GLP-1RAs May Lower Cardiac Adverse Event Risk in Psoriatic Arthritis
Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists is associated with a lower risk of developing major adverse cardiac events and mortality among patients with psoriatic arthritis.
A study presented at the American College of Rheumatology (ACR) Convergence 2025 found that GLP-1RAs were associated with lower risks for major adverse cardiac events, including heart failure, among patients with psoriatic arthritis.
Researchers from Jefferson Health in Philadelphia, Pennsylvania, conducted a retrospective study using data from the TriNetX database, including adults with psoriatic arthritis for the last 10 years.
Although previous research findings suggest that weight loss improves disease activity among patients with obesity and arthritis, data on the effect of GLP-1 receptor agonists on psoriatic arthritis remain limited.
The study was presented at the American College of Rheumatology (ACR) Convergence 2025, held in Chicago, Illinois from October 24 to 29, 2025.
Author's summary: GLP-1RAs may reduce cardiac risk in psoriatic arthritis.
More News
- Coup scare: DSS and selective use of state power
- Doubts about Trump’s wound to ear - Villages-News.com
- Voters hand Milei belated birthday present, post-mortem for Peronism overdue
- Editorial: We must stand in solidarity with the Indiana Daily Student, journalism everywhere - Daily Bruin
- Contractors submit UAE high-speed rail bids | MEED